Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis (AD)

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis (AD)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rocatinlimab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development

    • Most Recent Events

    • 14 Feb 2024 According to the Kyowa Kirin Media Release, data from this study will be presented at the upcoming American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego from March 8-12, 2024.
    • 11 Oct 2023 According to the Kyowa Kirin Media Release, the company announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083),in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.
    • 04 Oct 2023 According to the Kyowa Kirin Media Release, a post-hoc analysis and additional data will be presented at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany in October 11-14, 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top